Exalenz Bioscience named Roy Golab its president and CFO.
Here are four things to know about him.
1. Mr. Golan has more than 18 years experience in the healthcare and software industries. He also has extensive experience in finance.
2. He most recently served as NeuroDerm's CFO. He helped plan and execute the company's initial public offering in November 2014.
3. During his NeuroDerm tenure, Mr. Golan helped the company earn more than $200 million through their IPO, and he helped oversee the sale of NeuroDerm to Mitsubishi Tanabe Pharma Corp., for $1.1 billion in October 2017.
4. Mr. Golan said, "I am pleased to join Exalenz at this exciting time and to be part of realizing the tremendous value of our products and technologies."